Under a contract with the Henry M Jackson Foundation for the Advancement of Military Medicine, GenVec will receive funding for the development and preparation of vaccines related to this programme.
GenVec will design and manufacture the next generation vaccine candidates, which will use the company’s adenovector technology and be manufactured using its proprietary cell line.
NMRC will take up pre-clinical animal studies including studies in non-human primates.
GenVec expects that it will receive approximately $530,000 of revenue following the completion of work under the agreement with the Jackson Foundation in 2011.